25
Feb

Back in 2010, Ariad Pharmaceuticals’ ridaforolimus was a promising cancer therapy worth up to $700 million in the eyes of Merck. Now, in light of an FDA rejection and some dimming development prospects, Merck has quietly washed its hands of the drug, handing it back to its former partner.

…read more

Source: Merck scuttles a $700M-plus Ariad deal and hands back a once-vaunted cancer drug

    

0 No comments